National Systemic Anti-Cancer Therapy (SACT) consent forms – forms for lung cancer, supportive medicines and colorectal cancer published

Regimen-specific consent forms for the following tumour groups have been published on the Cancer Research UK website:

  • Lung cancer – 28 forms
  • Supportive medicines – 2 forms
  • Colorectal cancer – 22 forms

 
Please visit www.cruk.org/sact_consent to view and download the forms.  Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.
 
Please do not hesitate to contact Rena Chauhan (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected].
 
Victoria Fashina will be taking over as the lead pharmacist for the project from June 2017 (1 year maternity leave cover).  She can be contacted by email ([email protected]) if you have any queries or feedback in relation to the forms from June.

Rena Chauhan
12 May 2017
 

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article